FENNEC PHARMACEUTICALS INC.

Insider Trading Arrangements and Policies

Robert Andrade, the Company’s Chief Financial Officer, adopted a trading arrangement on May 22, 2026, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. This trading arrangement covers the disposition of up to 75,000 shares of the Company’s common stock, including shares issuable upon exercise of stock options, and will terminate on September 30, 2026, unless earlier terminated in accordance with its terms.

Marco Brughera, a current member of the Company’s Board of Directors, adopted a trading arrangement on June 16, 2026, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. This trading arrangement covers the disposition of up to 55,545 shares of the Company’s common stock, including shares issuable upon exercise of stock options, and will terminate on June 25, 2027, unless earlier terminated in accordance with its terms.

During the quarter ended June 30, 2026, no other director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulations S-K.

Press Release

On August 11, 2026, we issued a press release announcing our financial results for the quarter ended June 30, 2026. A copy of the news release is attached to this Quarterly Report as Exhibit 99.1. The press release is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references the press release.